For decades, cardiac troponin has been the preferred biomarker for helping to detect myocardial injury in acute care settings. The evolution of technology has led to the development of high sensitivity troponin assays that have greater precision at clinical decision points and enable lower limits of detection. This enhances clinicians ability to rule in or rule out acute myocardial infarction for timely intervention. Because of this, in 2018, "The Fourth Universal Definition of Myocardial Infarction" updated its guidelines to recommend the use of high sensitivity cardiac troponin assays that meet the precision criteria of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).¹

Understanding the clinical utility and differences in high sensitivity cardiac troponin assays, compared to previous generation products, is vital to their implementation in the healthcare system. Cardiac troponin values , whole number reporting, the presence of acute ischaemia in patients presenting with chest pain, and sex-specific cutoffs all play a role in AMI diagnosis using high sensitivity troponin testing.

This webinar provides an overview of the clinical guidelines supporting high sensitivity troponin, clinical benefits and key considerations when transitioning to a high sensitivity troponin assay.

Presenter: Lenette Walters

Lenette Walters is a Medical Technologist with a Master’s Degree in Biomedical Science. She has worked in the IVD industry for 26 years in a variety of positions with Beckman Coulter Diagnostics including Global Marketing Manager, and most recently serving as Director of Technical Support for the Immunoassay and Molecular Business Units, in Chaska, Minnesota. Lenette is currently a member of the Global Medical & Scientific Affairs team, supporting the implementation and utilization of the various product portfolios within the Diagnostics Division.